For the Inventor, By the Inventor

Enter assignee name

Daejeon, South Korea

Pharmabcine Inc.

USPTO Granted Patents = 10

CIPO Patents = 1

EPO Patents = 5

Forward Citations = 9

Loading Chart...

Loading Chart...

68 inventors (with patents filed for the assignee):

Weon Sup Lee (7 out of 7 patents)

Sang Soon Byun (6 out of 6 patents)

Jin-San Yoo (6 out of 7 patents)

4. Sung-Woo Kim (5 out of 9 patents)

5. Sang Ryeol Shim (5 out of 5 patents)

6. Jae Bong Yoon (4 out of 5 patents)

7. Do-Yun Kim (4 out of 6 patents)

8. Jin San Yoo (4 out of 4 patents)

9. Hyuk Jin Lee (4 out of 18 patents)

10. Miju Park (3 out of 3 patents)

11. Eun Hee Lee (3 out of 5 patents)

12. Jinsang Yoo (3 out of 3 patents)

13. Youngae Lee (3 out of 3 patents)

14. Chae-Ok Yun (3 out of 12 patents)

15. Weon-Sup Lee (3 out of 3 patents)

10 patents: Sort by Forward Citations

1. 11407834 - Anti-PD-L1 antibody and use thereof (2022-08-09),

2. 11407833 - Anti-VISTA antibody and use thereof (2022-08-09),

3. 10597457 - EGFRvIII antibody and composition comprising same (2020-03-24),

4. 10155817 - Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same (2018-12-18),

5. 10125194 - Dual targeting antibody of novel form, and use thereof (2018-11-13),

6. 10106622 - Human antibody specific to c-Met and preparation method thereof (2018-10-23),

7. 9963512 - Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same (2018-05-08),

8. 9249220 - Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof (2016-02-02),

9. 9249219 - Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof (2016-02-02),

10. 9150650 - Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof (2015-10-06),

Pharmabcine Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative antibody therapeutics for the treatment of cancer and other serious diseases. The company's lead product candidate, CT-2053, is currently in clinical trials for the treatment of advanced solid tumors. Pharmabcine Inc. is committed to improving the lives of patients through the advancement of cutting-edge biologics.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

10 Patents

#60 in Daejeon

#1,033 in South Korea

#54,324 in the World

Daejeon, South Korea

Pharmabcine Inc.

Forward Citations = 9

68 inventors:

Weon Sup Lee (7 out of 7 patents)

Sang Soon Byun (6 out of 6 patents)

Jin-San Yoo (6 out of 7 patents)

4. Sung-Woo Kim (5 out of 9 patents)

5. Sang Ryeol Shim (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…